Triple conventional synthetic disease-modifying anti-rheumatic drugs for the management of rheumatoid arthritis a review of cost-effectiveness
The aim of this report is to summarize the cost-effectiveness evidence on triple csDMARDs therapy (specifically, methotrexate, sulfasalazine, hydroxychloroquine) relative to other pharmacologic options for the management of RA in North America
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
CADTH
March 26, 2019, 2019
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references